Stockscreener 앱 받기
0.4533
6.16%
0.0263
시장 영업 전:
.46
0.0067
+1.48%
Werewolf Therapeutics Inc 주식(HOWL)의 최신 뉴스
Werewolf Therapeutics (HOWL) Stock Forum and Discussion - Moomoo
HOWL|Werewolf Therapeutics Inc|Price:0.427|Chg%:+0.067 - TradingKey
Werewolf Therapeutics Inc (HOWL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Werewolf Therapeutics, Inc. Revenue Breakdown – NASDAQ:HOWL - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Werewolf Therapeutics Inc (HOWL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
HOWL stock gains on latest Wolfpack earnings context - Ad-hoc-news.de
HOWL stock trades on fresh data from Werewolf Therapeutics cancer pipeline - Ad-hoc-news.de
Werewolf Therapeutics (HOWL) Q1 2026 Earnings: Narrower Loss Surprises as Biotech Navigates Early Pipeline MilestonesGross Profit Margin - dars.gov.et
Price to earnings forward of Werewolf Therapeutics, Inc. – NASDAQ:HOWL - TradingView
Frontier tech research, news & data - MLQ.ai
HOWL stock stays in focus as Werewolf Therapeutics pursues immuno-oncology pipeline - ad-hoc-news.de
Werewolf Therapeutics director Luke Evnin sells $44,749 in stock By Investing.com - Investing.com Nigeria
Form 4 Werewolf Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
Werewolf Therapeutics director Luke Evnin sells $44,749 in stock - Investing.com
Werewolf Therapeutics (HOWL) director-linked funds sell 143,199 shares - Stock Titan
Werewolf Therapeutics outlines its immuno-oncology strategy as Nasdaq-listed biotech - ad-hoc-news.de
Form 144 Werewolf Therapeutics For: 6 July By Investing.com - Investing.com Nigeria
[144] Werewolf Therapeutics, Inc. SEC Filing - Stock Titan
Werewolf Therapeutics, Inc. SEC Filing (Jul 6, 2026) - Stock Titan
RA Capital trims Werewolf Therapeutics (HOWL) stake below 5% threshold - Stock Titan
Form 13D/A WEREWOLF THERAPEUTICS For: 2 July By Investing.com - Investing.com South Africa
Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38 - MSN
Werewolf Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Werewolf Therapeutics director Luke Evnin sells $47,125 in stock By Investing.com - Investing.com Australia
Form 4 Werewolf Therapeutics Inc For: 29 June By Investing.com - Investing.com South Africa
Form 144 Werewolf Therapeutics For: 29 June By Investing.com - Investing.com South Africa
Werewolf Therapeutics director Luke Evnin sells $47,125 in stock - Investing.com
Entities tied to Werewolf Therapeutics (HOWL) director Luke Evnin sell 157K shares - Stock Titan
Werewolf Therapeutics, Inc. Actuals & Estimates (NASDAQ:HOWL) - TradingView
Form 13D/A WEREWOLF THERAPEUTICS For: 26 June By Investing.com - Investing.com South Africa
Werewolf Therapeutics Inc (HOWL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RA Capital reports 6% Werewolf Therapeutics (HOWL) stake after June share sales - Stock Titan
Werewolf Therapeutics details cancer pipeline progress, shares watched by biotech investors - ad-hoc-news.de
Werewolf Therapeutics Inc (HOWL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Werewolf Therapeutics Inc (HOWL) Institutional Confidence - TradingKey
Ra Capital sells $145,918 of Werewolf Therapeutics (HOWL) stock By Investing.com - Investing.com Australia
Ra Capital sells $145,918 of Werewolf Therapeutics (HOWL) stock - Investing.com UK
[SCHEDULE 13D/A] Werewolf Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Form 13D/A WEREWOLF THERAPEUTICS For: 22 June By Investing.com - Investing.com South Africa
Form 4 Werewolf Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
1.97%
0.83%
자본화:
|
볼륨(24시간):